Custom Peptide Synthesis Market Surges to $2.8B in 2026: 12.5% CAGR Driven by Oncology & GMP-Grade Innovations
Abstract: The custom peptide synthesis market is projected to reach $2.8 billion by 2026, growing at a 12.5% CAGR, driven by oncology therapeutics and GMP-grade innovations. Key trends include a shift toward high-purity (>98%) long-chain peptides and cGMP-certified facilities. Leading brands (e.g., Bachem, GenScript) compete on purity, yield, and scalability. Technical trade-offs involve cost vs. purity (HPLC vs. crude). Applications span targeted cancer drugs, vaccines, and diagnostics. Industry consolidation favors ISO 9001/GMP-certified factories. Logistics require cold-chain (-20°C) stability. Selection criteria prioritize purity certificates, batch consistency, and regulatory compliance.